Integra LifeSciences Holdings Corp. (IART) Wednesday said it has initiated a voluntary recall of certain specific lots of products, including DuraGen Dural Graft Matrix products, as the company identified that there may have been deviations from approved processes in their production.
These products were manufactured in its Anasco, Puerto Rico facility between December 2010 and May 2011 and between November 2012 and March 2013. The recall will affect Integra's profits for the first and second quarter.
There were no reports of adverse patient events attributable to the products subject to the recall, and the affected products continues to be manufactured in, and distribute from, the Anasco facility.
For the first-quarter, the company currently forecast a loss in the range of $0.30 to $0.08 per share, with adjusted earnings in the order of $0.30 to $0.40 per share. Revenues are projected in a range of $194 million to $197 million.
Analysts, based on consensus, currently expect the company to earn $0.69 per share on revenues of $204.69 million.
The company also expects to record incremental expense of approximately $2.5 million to $4.5 million, relating to the recall, during the quarter.
Meanwhile, the company anticipates second-quarter revenues in the range of $205 million to $211 million. Analysts expect revenues of $219.54 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.